Suppr超能文献

BTB/POZ 结构域蛋白 7:促进上皮间质转化和肝癌的预后生物标志物。

BTB/POZ domain-containing protein 7: epithelial-mesenchymal transition promoter and prognostic biomarker of hepatocellular carcinoma.

机构信息

Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, China.

出版信息

Hepatology. 2013 Jun;57(6):2326-37. doi: 10.1002/hep.26268.

Abstract

UNLABELLED

Epithelial-mesenchymal transition (EMT) is a critical step in the metastasis of hepatocellular carcinoma (HCC). BTB/POZ domain-containing protein 7 (BTBD7) regulates EMT-associated proteins implicated in HCC progression. However, the role(s) of BTBD7 in HCC have not been identified. Using highly metastatic HCC HCCLM3 cells, immortalized L02 hepatocytes, metastatic HCC animal models, and three independent cohorts of HCC patient specimens, we aimed to determine the involvement of BTBD7 in HCC metastasis. We show that BTBD7 messenger RNA and protein was highly expressed in HCC cells and tumor tissues, with such expression being associated with: enhanced cell motility, venous invasion, and poor prognosis. BTBD7 promoted HCC angiogenesis and metastasis in vitro and in vivo, but did not influence cell proliferation or colony formation. BTBD7 enhancement of HCC invasion and EMT phenotype occurred through activation of a RhoC-Rock2-FAK-signaling pathway, resulting in matrix metalloproteinase-2/9 production and microvessel formation. Applying a predictive risk score model, Cox regression analysis revealed that high BTBD7 expression integrated with high microvessel density was a powerful independent predictive factor of HCC clinical outcome.

CONCLUSION

The present study identifies BTBD7 as a novel candidate prognostic factor and a potential therapeutic target of HCC. (HEPATOLOGY 2013; 57:2326-2337).

摘要

未加标签

上皮-间充质转化(EMT)是肝细胞癌(HCC)转移的关键步骤。BTB/POZ 结构域蛋白 7(BTBD7)调节 EMT 相关蛋白,这些蛋白与 HCC 进展有关。然而,BTBD7 在 HCC 中的作用尚未确定。使用高转移性 HCC HCCLM3 细胞、永生化 L02 肝细胞、转移性 HCC 动物模型和三个独立的 HCC 患者标本队列,我们旨在确定 BTBD7 是否参与 HCC 转移。我们表明,BTBD7 信使 RNA 和蛋白质在 HCC 细胞和肿瘤组织中高表达,这种表达与增强的细胞迁移性、静脉侵犯和不良预后相关。BTBD7 在体外和体内促进 HCC 血管生成和转移,但不影响细胞增殖或集落形成。BTBD7 通过激活 RhoC-Rock2-FAK 信号通路增强 HCC 的侵袭和 EMT 表型,导致基质金属蛋白酶-2/9 的产生和微血管形成。应用预测风险评分模型,Cox 回归分析显示,高 BTBD7 表达与高微血管密度相结合是 HCC 临床结局的一个强有力的独立预测因素。

结论

本研究确定 BTBD7 是 HCC 的一个新的候选预后因素和潜在的治疗靶点。(《肝脏病学》2013 年;57 卷:2326-2337)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验